Wang Han-Qi, Fu Ruxing, Man Qi-Wen, Yang Guang, Liu Bing, Bu Lin-Lin
The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) & Key Laboratory of Oral Biomedicine Ministry of Education, School & Hospital of Stomatology, Wuhan University, Wuhan 430072, China.
Department of Oral & Maxillofacial Head Neck Oncology, School & Hospital of Stomatology, Wuhan University, Wuhan 430072, China.
J Clin Med. 2023 Mar 10;12(6):2173. doi: 10.3390/jcm12062173.
Surgery with the assistance of conventional radiotherapy, chemotherapy and immunotherapy is the basis for head and neck squamous cell carcinoma (HNSCC) treatment. However, with these treatment modalities, the recurrence and metastasis of tumors remain at a high level. Increasingly, the evidence indicates an excellent anti-tumor effect of chimeric antigen receptor T (CAR-T) cells in hematological malignancy treatment, and this novel immunotherapy has attracted researchers' attention in HNSCC treatment. Although several clinical trials have been conducted, the weak anti-tumor effect and the side effects of CAR-T cell therapy against HNSCC are barriers to clinical translation. The limited choices of targeting proteins, the barriers of CAR-T cell infiltration into targeted tumors and short survival time in vivo should be solved. In this review, we introduce barriers of CAR-T cell therapy in HNSCC. The limitations and current promising strategies to overcome barriers in solid tumors, as well as the applications for HNSCC treatment, are covered. The perspectives of CAR-T cell therapy in future HNSCC treatment are also discussed.
在传统放疗、化疗和免疫治疗的辅助下进行手术是头颈部鳞状细胞癌（HNSCC）治疗的基础。然而，采用这些治疗方式时，肿瘤的复发和转移率仍然很高。越来越多的证据表明，嵌合抗原受体T（CAR-T）细胞在血液系统恶性肿瘤治疗中具有出色的抗肿瘤效果，这种新型免疫疗法在HNSCC治疗中已引起研究人员的关注。尽管已经开展了多项临床试验，但CAR-T细胞疗法对HNSCC的抗肿瘤效果较弱以及存在副作用，这些都是临床转化的障碍。靶向蛋白选择有限、CAR-T细胞浸润到靶向肿瘤的障碍以及体内存活时间短等问题都有待解决。在这篇综述中，我们介绍了CAR-T细胞疗法在HNSCC中的障碍。涵盖了实体瘤中克服障碍的局限性和当前有前景的策略，以及在HNSCC治疗中的应用。还讨论了CAR-T细胞疗法在未来HNSCC治疗中的前景。
